Risk assessment and prevention of sudden death in hypertrophie cardiomyopathy;Cardiomiopatia ipertrofica e morte improvvisa

Recenti Progressi in Medicina

Volumn 92, Issue 3, 2001, Pages 205-208

  Piccininno, Marco ^a   Spirito, Paolo ^a  

^a GALLIERA HOSPITAL   (Italy)

Author keywords

Hypertrophic cardiomyopathy; Sudden death

Indexed keywords

HUMAN; HYPERTROPHIC CARDIOMYOPATHY; PREVALENCE; REVIEW; RISK FACTOR; SUDDEN DEATH;

CARDIOMYOPATHY, HYPERTROPHIC; DEATH, SUDDEN; HUMANS; PREVALENCE; RISK FACTORS;

EID: 0035290185     PISSN: 00341193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Teare D. Asymmetrical hypertrophy of the heart in young adults. Br Heart J 1958; 20: 1-8.
2. Maron BJ, Bonow RO, Cannon RO III, et al. Hypertrophic cardiomyopathy: interrelations of clinical manifestations, pathophysiology, and therapy. N Engl J Med 1987; 316: 780-9, and 844-52.
3. Spirito P, Chiarella F, Carratino L, et al. Clinical course and prognosis of hypertrophic cardiomyopathy in a a outpatient population. N Engl J Med 1989; 320: 749-55.
4. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997; 336: 775-85.
5. Watkins H, Rosenzweig A, Hwang DS, et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 1992; 326: 1108-14.
6. Thierfelder L, Watkins H, MacRae C, et al. Alfa-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Ceil 1994; 77: 701-12.
7. Maron BJ, Casey SA, Poliac LC, et al. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999; 281: 650-5.
8. Spirito P, Rapezzi C, Autore C, et al. Prognosis in asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation 1994; 90: 2743-7.
9. Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA Study. Circulation 1995; 92: 785-9.
10. Corrado D, Basso C, Schiavon M, Thiene G. Screening for hypertrophic cardiomyopathy in young athletes. N Engl J Med 1998; 339: 364-9.
11. Klues HG, Schiffers A, Maron BJ. Phenotipic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol 1995; 26: 1699-708.
12. Maron BJ, Shen WK, Link MS et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000; 342: 365-73.
13. Spirito P, Bellone P, Harris KM, et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000; 342: 1778-85.
14. McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 1985; 53: 412-6.